# Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy

> **NIH NIH R01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $168,429

## Abstract

The pandemic caused by SARS-CoV-2 has killed 430,000 people worldwide in the span of 6 months which
overall place cancer patients at a higher risk of severe illness and death if infected, although differences between
distinct therapy regimens are possible (e.g. chemotherapy vs. immunotherapy vs. palliation). Cancer patients
who have recovered from COVID-19 may need to resume treatment, including immunotherapy for their disease
even though the repercussions of this infection on their immune systems are unknown. This project will determine
if cancer patients who have recovered from COVID-19 have NK cells with different functionality than cancer
patients who were not infected, and whether these phenotypes have an impact on the overall response rate and
survival of this population.

## Key facts

- **NIH application ID:** 10203557
- **Project number:** 3R01CA201189-05S1
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Nina Bhardwaj
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $168,429
- **Award type:** 3
- **Project period:** 2020-07-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10203557

## Citation

> US National Institutes of Health, RePORTER application 10203557, Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy (3R01CA201189-05S1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10203557. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*